» Articles » PMID: 38510810

Combination Radiofrequency Ablation and Vertebral Cement Augmentation for Spinal Metastatic Tumors: A Systematic Review and Meta-analysis of Safety and Treatment Outcomes

Overview
Date 2024 Mar 21
PMID 38510810
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The treatment of spine metastases continues to pose a significant clinical challenge, requiring the integration of multiple therapeutic modalities to address the multifactorial aspects of this disease process. Radiofrequency ablation (RFA) and vertebral cement augmentation (VCA) are 2 less invasive modalities compared to open surgery that have emerged as promising strategies, offering the potential for both pain relief and preservation of vertebral stability. The utility of these approaches, however, remains uncertain and subject to ongoing investigation.This systematic review and meta-analysis evaluates the available evidence and synthesize the results of studies that have investigated the combination of RFA and VCA for the treatment of spinal metastases, with the goal of providing a comprehensive and up-to-date assessment of the efficacy and safety of this therapeutic approach.

Methods: A literature search was conducted using the electronic databases PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus from their inception to May 4th, 2022 in accordance with PRISMA guidelines. Studies were included if they met the following criteria: 1) spine metastases treated with RFA in combination with VCA, 2) available data on at least one outcome (i.e., pain palliation, complications, local tumor control), 3) prospective or retrospective studies with at least 10 patients, and 4) English language. Meta-analyses were conducted in R (R Foundation for Statistical Computing; Vienna, Austria), using the package.

Results: In the 25 included studies, a total of 947 patients (females=53.9%) underwent RFA + VCA for spinal metastatic tumors. Out of 1,163 metastatic lesions, the majority were located in the lumbar region (585/1,163 [50.3%]) followed by thoracic (519/1,163 [44.6%]), sacrum (39/1,163 [3.4%]), and cervical (2/1,163 [0.2%]). 48/72 [66.7%] metastatic lesions expanded into the posterior elements. Preoperative pathologic vertebral fractures were identified in 115/176 [65.3%] patients. Between pre-procedure pain scores and postprocedure pain scores, average follow-up (FU) was 4.41±2.87 months. Pain scores improved significantly at a short-term FU (1-6 months), with a pooled mean difference (MD) from baseline of 4.82 (95% CI, 4.48-5.16). The overall local tumor progression (LTP) rate at short-term FU (1-6 months) was 5% (95% CI, 1%-8%), at mid-term FU (6-12 months) was 22% (95% CI, 0%-48%), and at long-term FU (>12 months) was 5% (95% CI, 0%-11%). The pooled incidence of total complications was 1% (95% CI, 0%-1%), the most frequent of which were transient radicular pain and asymptomatic cement extravasation.

Conclusions: The findings of this meta-analysis reveal that the implementation of RFA in conjunction with VCA for the treatment of spinal metastatic tumors resulted in a significant short-term reduction of pain, with minimal total complications. The LTP rate was additionally low. The clinical efficacy and safety of this technique are established, although further exploration of the long-term outcomes of RFA+VCA is warranted.

Citing Articles

Evaluating the Accuracy and Efficiency of Imaging Modalities in Guiding Ablation for Metastatic Spinal Column Tumors: A Systematic Review.

Aslan S, Al-Smadi M, Al-Khafaji M, Gati A, Al-Khafaji M, Viola R Cancers (Basel). 2024; 16(23).

PMID: 39682134 PMC: 11640510. DOI: 10.3390/cancers16233946.


Complication avoidance, rehabilitation, pain therapy and palliative care for patients with metastatic spine tumors: WFNS spine committee recommendations.

Pojskic M, Naderi S, Vaishya S, Zileli M, Costa F, Sharif S Neurosurg Rev. 2024; 47(1):830.

PMID: 39476270 PMC: 11525440. DOI: 10.1007/s10143-024-03050-3.

References
1.
Aman M, Mahmoud A, Deer T, Sayed D, Hagedorn J, Brogan S . The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain. J Pain Res. 2021; 14:2139-2164. PMC: 8292624. DOI: 10.2147/JPR.S315585. View

2.
Levy J, Hopkins T, Morris J, Tran N, David E, Massari F . Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. J Vasc Interv Radiol. 2020; 31(11):1745-1752. DOI: 10.1016/j.jvir.2020.07.014. View

3.
Yang P, He X, Li H, Zang Q, Wang G . Image-guided minimally invasive percutaneous treatment of spinal metastasis. Exp Ther Med. 2017; 13(2):705-709. PMC: 5348712. DOI: 10.3892/etm.2017.4029. View

4.
Yildizhan S, Boyaci M, Rakip U, Aslan A, Canbek I . Role of radiofrequency ablation and cement injection for pain control in patients with spinal metastasis. BMC Musculoskelet Disord. 2021; 22(1):912. PMC: 8556885. DOI: 10.1186/s12891-021-04799-0. View

5.
Figura N, Smith J, Yu H . Mechanisms of, and Adjuvants for, Bone Pain. Hematol Oncol Clin North Am. 2018; 32(3):447-458. DOI: 10.1016/j.hoc.2018.01.006. View